Truetide’s Paraytec Wraps Up Phase 2 of Lung Cancer Trial

Truetide’s Paraytec announced today that it has successfully completed Phase 2 of its lung‑cancer study. The multicenter trial evaluated the investigational therapy in patients with advanced non‑small cell lung cancer, meeting its primary efficacy endpoints while maintaining a favorable safety profile. The company said it will use these data to design a Phase 3 program aimed at further assessing the drug’s clinical benefits in a larger patient population.